Mulitcenter Study of Options for SEcond-Line Effective Combination Therapy (SELECT)
Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID)
Protocol Summary: A5273 is a phase III, dual-arm, open-label, randomized, non-inferiority study for participants who are on a failing non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing first-line regimen. The study will evaluate the difference in virologic failure rate between two treatment arms: lopinavir/ritonavir plus raltegravir (LPV/r + RAL) and LPV/r plus best available nucleos(t)ide reverse transcriptase inhibitors (NRTIs).
Years: 2012 – 2014
Investigator: Anthony Chisada
Location: Parirenyatwa CRS